Antioxidant effects of statins in the management of cardiometabolic disorders

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 10, 2014, Pages 997-1010

  Lim, Soo ^a   Barter, Prilip ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antioxidant; Cardiometabolic disorders; Reactive oxygen species; Redox; Statin

Indexed keywords

ANTIOXIDANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

DISEASE COURSE; HEART DISEASES; HUMAN; INSULIN RESISTANCE; METABOLIC DISEASES; OXIDATION REDUCTION REACTION;

ANTIOXIDANTS; DISEASE PROGRESSION; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; METABOLIC DISEASES; OXIDATION-REDUCTION;

EID: 84908202446     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.24398     Document Type: Review

References (150)

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Prito R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681
2. Ford I, Murray H, P.ckard CJ, Shepherd J, Macfarlane P., Cobbe SM: Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med, 2007; 357: 1477-1486
3. Colhoun HM, Betteridge DJ, Durrington P., Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696
4. Jialal I, Stein D, Balis D, Grundy SM, ms-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001; 103: 1933-1935
5. Sparrow CP. Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang P., Zhang D, Peterson L, Detmers P., Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol, 2001; 21: 115-121
6. Stoll LL, McCormick ML, Denning GM, Weintraub NL: Antioxidant effects of statins. Drugs Today (Barc), 2004; 40: 975-990
7. Lim S, Sakuma I, Quon MJ, Koh KK: Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal, 2014; 20: 1286-1299
8. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P. Schwartz JS, Shero ST, Smith SC, Jr., Watson K, Wilson P.: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129 (25 Suppl 2): S1-S45
9. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg, 2008; 70: 193-219
10. Albertini R, Moratti R, De LG: Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies. Curr Mol Med, 2002; 2: 579-592
11. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002; 22: 300-305
12. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol, 2000; 20: 61-69
13. Itabe H: Oxidized low-density lipoproteins: what is understood and what remains to be clarified. Biol Prarm Bull, 2003; 26: 1-9
14. Steinberg D: The LDL modification hypothesis of atherogenesis: an update. J Lipid Res, 2009; 50 Suppl: S376-S381
15. Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004; 173: 1-12
16. Del P., Zaccagnino P. Di P., Saltarella M, Oliveros CC, Nico B, Santoro G, Lorusso M: Role of mitochondria and reactive oxygen species in dendritic cell differentiation and functions. Free Radic Biol Med, 2008; 44: 1443-1451
17. Nicco C, Laurent A, Chereau C, Weill B, Batteux F: Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed Prarmacother, 2005; 59: 169-174
18. Wolf G: Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. Antioxid Redox Signal, 2005; 7: 1337-1345
19. Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH: Reactive oxygen species and molecular biology of ischemia/ reperfusion. Ann Transplant, 2004; 9: 81-83
20. Colavitti R, Finkel T: Reactive oxygen species as mediators of cellular senescence. IUBMB Life, 2005; 57: 277-281
21. Delles C, Miller WH, Dominiczak AF: Targeting reactive oxygen species in hypertension. Antioxid Redox Signal, 2008; 10: 1061-1077
22. Patel RP. Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, rley-Usmar VM: Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med, 2000; 28: 1780-1794
23. Padrini C, Borghesan M, Greco A, Przienza V, Mazzoccoli G, Vinciguerra M: Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD). Curr Prarm Des, 2013; 19: 2737-2746
24. Bagi Z, Feher A, Beleznai T: Preserved coronary arteriolar dilatation in patients with type 2 diabetes mellitus: implications for reactive oxygen species. Prarmacol Rep, 2009; 61: 99-104
25. Morel DW, DiCorleto P., Chisolm GM: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis, 1984; 4: 357-364
26. Lamb DJ, Wilkins GM, Leake DS: The oxidative modification of low density lipoprotein by human lymphocytes. Atherosclerosis, 1992; 92: 187-192
27. Yoshida H, Kisugi R: Mechanisms of LDL oxidation. Clin Chim Acta, 2010; 411: 1875-1882
28. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol, 2002; 22: 1649-1654
29. Itabe H, Takano T: Oxidized low density lipoprotein: the occurrence and metabolism in circulation and in foam cells. J Atheroscler Thromb, 2000; 7: 123-131
30. Chen HW, Kuo CL, Huang CS, Kuo SJ, Liu CS: Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population. Cardiology, 2008; 110: 252-259
31. Koenig W, Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, Thorand B: Oxidized LDL and the risk of coronary heart disease: results from the MONICA/ KORA Augsburg Study. Clin Chem, 2011; 57: 1196-1200
32. Luoma JS, Kareinen A, Narvanen O, Viitanen L, Laakso M, Yla-Herttuala S: Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radic Biol Med, 2005; 39: 1660-1665
33. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, Takano T: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem, 1994; 269: 15274-15279
34. de Boer OJ, van der Wal AC, Becker AE: Atherosclerosis, inflammation, and infection. J Prthol, 2000; 190: 237-243
35. Becker AE, de Boer OJ, van Der Wal AC: The role of inflammation and infection in coronary artery disease. Annu Rev Med, 2001; 52: 289-297
36. Biasucci LM, Cardillo MT: Biomarkers of inflammation and endothelial function: the holy grail of experimental and clinical medicine? Vascul Prarmacol, 2012; 56: 26-28
37. Madjid M, Willerson JT: Inflammatory markers in coronary heart disease. Br Med Bull, 2011; 100: 23-38
38. Cipollone F, Mezzetti A, Pirreca E, Di FC, Nutini M, Fazia M, Falco A, Cuccurullo F, Davi G: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation, 2002; 106: 399-402
39. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res, 2002; 90: 251-262
40. Barnes P., Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997; 336: 1066-1071
41. DeForge LE, Fantone JC, Kenney JS, Remick DG: Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood. J Clin Invest, 1992; 90: 2123-2129
42. Sasaki S, Inoguchi T: The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J, 2012; 36: 255-261
43. Vamecq J, Dessein AF, Fontaine M, Briand G, Pirchet N, Latruffe N, Andreolotti P. Cherkaoui-Malki M: Mitochondrial dysfunction and lipid homeostasis. Curr Drug Metab, 2012; 13: 1388-1400
44. Schrauwen P. Schrauwen-Hinderling V, Hoeks J, Hesselink MK: Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta, 2010; 1801: 266-271
45. Calabrese V, Cornelius C, Leso V, Trovato-Salinaro A, Ventimiglia B, Cavallaro M, Scuto M, Rizza S, Zanoli L, Neri S, Castellino P. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta, 2012; 1822: 729-736
46. Mokini Z, Chiarelli F: The molecular basis of diabetic microangiopathy. P.diatr Endocrinol Rev, 2006; 4: 138-152
47. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M: TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med, 2006; 6: 351-358
48. Srivastava SK, Ramana KV, Bhatnagar A: Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev, 2005; 26: 380-392
49. Yan SF, Ramasamy R, Naka Y, Schmidt AM: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res, 2003; 93: 1159-1169
50. Hammes HP. Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P. Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med, 2003; 9: 294-299
51. Yamada K, Hara N, Shibata T, Osago H, Tsuchiya M: The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem, 2006; 352: 282-285
52. Blinova K, Carroll S, Bose S, Smirnov AV, Harvey JJ, Knutson JR, Balaban RS: Distribution of mitochondrial NADH fluorescence lifetimes: steady-state kinetics of matrix NADH interactions. Biochemistry, 2005; 44: 2585-2594
53. Todisco S, Agrimi G, Castegna A, Palmieri F: Identification of the mitochondrial NAD＋ transporter in Saccharomyces cerevisiae. J Biol Chem, 2006; 281: 1524-1531
54. Ying W: NAD＋/NADH and NADP.amp;#65291;/NADP. in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal, 2008; 10: 179-206
55. Sugden MC, Holness MJ: Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Arch Physiol Biochem, 2006; 112: 139-149
56. Blatnik M, Frizzell N, Thorpe SR, Baynes JW: Inactivation of glyceraldehyde-3-phosphate dehydrogenase by fumarate in diabetes: formation of S-(2-succinyl)cysteine, a novel chemical modification of protein and possible biomarker of mitochondrial stress. Diabetes, 2008; 57: 41-49
57. Codoner-Franch P. Navarro-Ruiz A, Fernandez-Ferri M, rilla-Codoner A, Ballester-Asensio E, Valls-Belles V: A matter of fat: insulin resistance and oxidative stress. Pediatr Diabetes, 2012; 13: 392-399
58. Sankhla M, Sharma TK, Mathur K, Rathor JS, Butolia V, Gadhok AK, Vardey SK, Sinha M, Kaushik GG: Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab, 2012; 58: 385-392
59. Brasil AR, Norton RC, Rossetti MB, Leao E, Mendes RP. C-reactive protein as an indicator of low intensity inflammation in children and adolescents with and without obesity. J Pediatr (Rio J), 2007; 83: 477-480
60. Reyes M, Gahagan S, Diaz E, Blanco E, Leiva L, Lera L, Burrows R: Relationship of adiposity and insulin resistance mediated by inflammation in a group of overweight and obese Chilean adolescents. Nutr J, 2011; 10: 4
61. Executive Summary of The Third Report of The National Cholesterol Education Program NCEP. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel Ⅲ). JAMA, 2001; 285: 2486-2497
62. Yamagishi S, Matsuoka H, Kitano S, Hibi N, Jinnouchi Y, Umei H, Iida S, Takenaka K, Matsui T, Nakamura K, Imaizumi T: Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. Int J Cardiol, 2007; 118: 270-272
63. Holvoet P. Lee DH, Steffes M, Gross M, Jacobs DR, Jr.: Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA, 2008; 299: 2287-2293
64. Colas R, Sassolas A, Guichardant M, Cugnet-Anceau C, Moret M, Moulin P. Lagarde M, Calzada C: LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets. Diabetologia, 2011; 54: 2931-2940
65. Segers D, Helderman F, Cheng C, van Damme LC, Tempel D, Boersma E, Serruys P., de CR, van der Steen AF, Holvoet P. Krams R: Gelatinolytic activity in atherosclerotic plaques is highly localized and is associated with both macrophages and smooth muscle cells in vivo. Circulation, 2007; 115: 609-616
66. Masella R, Vari R, D’Archivio M, Santangelo C, Scazzocchio B, Maggiorella MT, Sernicola L, Titti F, Sanchez M, Di MU, Leto G, Giovannini C: Oxidised LDL modulate adipogenesis in 3T3-L1 preadipocytes by affecting the balance between cell proliferation and differentiation. FEBS Lett, 2006; 580: 2421-2429
67. Padrez EA: Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol, 2010; 37: 719-725
68. Lu C, Gao Y, Zhou H, Tian H: The relationships between PAN1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose. Coron Artery Dis, 2008; 19: 565-573
69. Holvoet P. Davey P., De KD, Doukoure M, Deridder E, Bochaton-Phallat ML, Gabbiani G, Beaufort E, Bishay K, Andrieux N, Benhabiles N, Marguerie G: Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP.1 cells. Arterioscler Thromb Vasc Biol, 2006; 26: 1558-1565
70. Smith BW, Adams LA: Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol, 2011; 7: 456-465
71. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK: NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol, 2009; 104: 861-867
72. Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP. Kato N, Wickremasinghe AR, de Silva HJ: Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol, 2013; 28: 142-147
73. Gariani K, Philippe J, Jornayvaz FR: Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab, 2013; 39: 16-26
74. Boddi M, Tarquini R, Chiostri M, Marra F, Valente S, Giglioli C, Gensini GF, Abbate R: Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest, 2013; 43: 429-438
75. Targher G, Arcaro G: Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 2007; 191: 235-240
76. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 2010; 51: 1820-1832
77. Ha HL, Yu DY: HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of P.EN/Akt pathway. World J Gastroenterol, 2010; 16: 4932-4937
78. Savu O, Sunkari VG, Botusan IR, Grunler J, Nikoshkov A, Catrina SB: Stability of mitochondrial DNA against reactive oxygen species (ROS) generated in diabetes. Diabetes Metab Res Rev, 2011; 27: 470-479
79. Begriche K, Igoudjil A, Pessayre D, Fromenty B: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion, 2006; 6: 1-28
80. Koonen DP. Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE, Dyck JR: Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes, 2007; 56: 2863-2871
81. Chabowski A, Zendzian-Photrowska M, Konstantynowicz K, Pinkiewicz W, Miklosz A, Lukaszuk B, Gorski J: Fatty acid transporters involved in the palmitate and oleate induced insulin resistance in primary rat hepatocytes. Acta Physiol (Oxf), 2013; 207: 346-357
82. Cai L, Wang Z, Ji A, Meyer JM, van der Westhuyzen DR: Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in dietinduced obesity. PloS One, 2012; 7: e36785
83. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008; 28: 27-38
84. Yki-Jarvinen H: Fat in the liver and insulin resistance. Ann Med, 2005; 37: 347-356
85. Rogowski O, Shapira I, Steinvil A, Berliner S: Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: another feature of the atherogenic dysmetabolism. Metabolism, 2009; 58: 661-667
86. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pleffer MA, Braunwald E: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation, 1998; 97: 1446-1452
87. LaRosa JC: Statins risk of coronary heart disease. JAMA, 2000; 283: 2935-2936
88. Manuel DG, Kwong K, Tanuseputro P. Lim J, Mustard CA, Anderson GM, Ardal S, Alter DA, Laupacis A: Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ, 2006; 332: 1419
89. Coleman CI, Reinhart K, Kluger J, White CM: The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin, 2008; 24: 1359-1362
90. Pilisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Westendorp RG, de Craen AJ, Buckley BM, Ordovas JM, Schaefer EJ: Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in P.OSP.R. Atherosclerosis, 2008; 200: 109-114
91. Pleiss D, Seshasai SR, Welsh P. Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P. Cannon CP. Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Padersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 2011; 305: 2556-2564
92. Koh KK, Sakuma I, Quon MJ: Differential metabolic effects of distinct statins. Atherosclerosis, 2011; 215: 1-8
93. Koh KK, Lim S, Sakuma I, Quon MJ: Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol, 2012; 154: 97-101
94. Girona J, La Ville AE, Sola R, Phana N, Masana L: Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol, 1999; 83: 846-851
95. Yamamoto A, Ichihara K, Hoshi K: Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes. J Pharm Pharmacol, 2001; 53: 227-232
96. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis, 2001; 154: 87-96
97. Karatzis E, Lekakis J, Pepamichael C, Andreadou I, Cimponeriu A, Aznaouridis K, Pepaioannou TG, Photogerou A, Mavrikakis M: Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. Int J Cardiol, 2005; 101: 65-70
98. Rapoport RM, Draznin MB, Murad F: Endotheliumdependent relaxation in rat aorta may be mediated through cyclic GMP.dependent protein phosphorylation. Nature, 1983; 306: 174-176
99. Bredt DS, Snyder SH: Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem, 1994; 63: 175-195
100. Clancy RM, Abramson SB: Nitric oxide: a novel mediator of inflammation. Proc Soc Exp Biol Med, 1995; 210: 93-101
101. Thomassen MJ, Buhrow LT, Connors MJ, Kaneko FT, Erzurum SC, Kavuru MS: Nitric oxide inhibits inflammatory cytokine production by human alveolar macrophages. Am J Respir Cell Mol Biol, 1997; 17: 279-283
102. Hill JR, Corbett JA, Kwon G, Marshall CA, McDaniel ML: Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages. J Biol Chem, 1996; 271: 22672-22678
103. Wang Y, Marsden P.: Nitric oxide synthases: gene structure and regulation. Adv Pharmacol, 1995; 34: 71-90
104. Wassmann S, Nickenig G: Interrelationship of free oxygen radicals and endothelial dysfunction--modulation by statins. Endothelium, 2003; 10: 23-33
105. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E: Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol, 2000; 36: 617-621
106. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G: Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res, 2003; 93: e98-e103
107. Laufs U, Liao JK: Past-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem, 1998; 273: 24266-24271
108. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000; 6: 1004-1010
109. Feron O, Dessy C, Desager JP. Balligand JL: Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation, 2001; 103: 113-118
110. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP. Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y: Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol, 2006; 290: H1960-H1968
111. Cangemi R, Loffredo L, Carnevale R, Parri L, Patrizi MP. Sanguigni V, Pagnatelli P. Violi F: Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J, 2008; 29: 54-62
112. Pagnatelli P. Carnevale R, Postori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F: Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation, 2012; 126: 92-103
113. Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, Matsuzaki M: Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol, 2006; 291: H2522-H2532
114. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N: Vascular lipotoxicity: endothelial dysfunction via fattyacid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology, 2007; 148: 160-165
115. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G: Inhibition of geranylgeranylation reduces angiotensin Ⅱ-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 2001; 59: 646-654
116. Jeon SM, Bok SH, Jang MK, Lee MK, Nam KT, Park YB, Rhee SJ, Choi MS: Antioxidative activity of naringin and lovastatin in high cholesterol-fed rabbits. Life Sci, 2001; 69: 2855-2866
117. Schupp N, Schmid U, Heidland A, Stopper H: Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis, 2008; 199: 278-287
118. Honjo T, Inoue N, Shiraki R, Kobayashi S, Otsui K, Takahashi M, Hirata K, Kawashima S, Yokozaki H, Yokoyama M: Endothelial urocortin has potent antioxidative properties and is upregulated by inflammatory cytokines and pitavastatin. J Vasc Res, 2006; 43: 131-138
119. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, Havekes LM: Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in AP.E＊3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation, 2003; 108: 1368-1374
120. Ridker P., Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation, 2003; 107: 391-397
121. Rice JB, Stoll LL, Li WG, Denning GM, Weydert J, Charipar E, Richenbacher WE, Miller FJ, Jr., Weintraub NL: Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol, 2003; 23: 1576-1582
122. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP. Ares MP. Nilsson J, Pachinger O, Weidinger F: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2003; 23: 58-63
123. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, Robbie L, Ganz P. Kinlay S, Libby P. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation, 2002; 106: 2888-2893
124. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ: Statins suppress THP.1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol, 2001; 69: 959-962
125. Crisby M, Nordin-Fredriksson G, Shah P., Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 2001; 103: 926-933
126. Barter P., Brandrup-Wognsen G, Palmer MK, Nicholls SJ: Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res, 2010; 51: 1546-1553
127. Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol, 2007; 47: 135-141
128. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K: Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism, 2008; 57: 1711-1718
129. Abel T, Feher J, Dinya E, Eldin MG, Kovacs A: Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit, 2009; 15: MS6-11
130. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G: Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis, 2006; 184: 233-234
131. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA: A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebocontrolled trial. J Clin Gastroenterol, 2009; 43: 990-994
132. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K: Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res, 2012; 42: 1065-1072
133. Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tokumo H, Hino F, Tazuma S: Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res, 2011; 41: 1057-1065
134. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A: Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol, 2003; 38: 564-572
135. Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C: Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitisrelated liver fibrosis. PloS One, 2013; 8: e76538
136. Argo CK, Loria P. Caldwell SH, Lonardo A: Statins in liver disease: a molehill, an iceberg, or neither? Hepatology, 2008; 48: 662-669
137. Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K: Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property. Dig Liver Dis, 2012; 44: 492-496
138. Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, Kimura H, Nishimura T, Tochiki N, Yasui K, Mitsuyoshi H, Minami M, Kagawa K, Okanoue T, Itoh Y: Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int, 2013; 33: 301-311
139. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K: Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol, 2010; 45: 750-757
140. Padszun MC, Grebenstein N, Spruss A, Schlueter T, Kremoser C, Bergheim I, Frank J: Dietary alpha-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of guinea pigs. J Nutr Biochem, 2014; 25: 573-579
141. Ridker P., Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P. Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207
142. Sattar N, Pleiss D, Murray HM, Welsh P. Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane P., Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Plessel SL, Marchioli R, Marfisi RM, Maggioni AP. Tavazzi L, Tognoni G, Kjekshus J, Padersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742
143. Chamberlain LH: Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett, 2001; 507: 357-361
144. Kanda M, Satoh K, Ichihara K: Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull, 2003; 26: 1681-1684
145. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem, 2003; 278: 45021-45026
146. Motoshima H, Wu X, Mahadev K, Goldstein BJ: Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun, 2004; 315: 264-271
147. Teramoto T, Shimano H, Yokote K, Urashima M: New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother, 2010; 11: 817-828
148. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK: Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis, 2009; 204: 483-490
149. Chapman MJ, Orsoni A, Robillard P. Hounslow N, Sponseller CA, Giral P. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPTAIN and PREVAIL-US studies. Curr Med Res Opin, 2014
150. Lim S, Sakuma I, Quon MJ, Koh KK: Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol, 2013; 167: 1696-1702